ClinicalTrials.Veeva

Menu

Multimodality Imaging Assessment of the Severity of Mitral Regurgitation

Sun Yat-sen University logo

Sun Yat-sen University

Status

Enrolling

Conditions

Mitral Regurgitation

Treatments

Other: rehydration
Diagnostic Test: CMR
Other: fasting
Diagnostic Test: UCG

Study type

Interventional

Funder types

Other

Identifiers

NCT06266858
SYSKY-2022-407-02

Details and patient eligibility

About

To investigate to assess the severity of mitral regurgitation by multimodality imaging.

Full description

In the single-center and open-label study, the researcher will compare the changes of ultrasonic cardiography (UCG) parameters when patients in fasting, anaesthesia and rehydration firstly. The aims are to clarify the effect of fasting and anaesthesia on the assessment of mitral regurgitation (MR) severity and the corrective effect of intravenous rehydration. The researcher then will investigate the correlation and consistency of multimodality imaging in assessing the severity of mitral regurgitation. The aim is to acquire more accurate, objective and reproducible parameters, to provide new solution for the precise assessment of MR severity and to guide the selection of clinical treatment and timing.

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. age ≥ 18 years old
  2. all-caused moderate or severe MR assessed by Trans-Thoracic Echocardiography (TTE) : 1) EROA ≥0.3cm^2; 2) RVol ≥45ml
  3. The patient has signed an informed consent form.

Exclusion criteria

  1. unstable angina, acute myocardial infarction and surgical history of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) within 3 months before recruit
  2. acute heart failure or acute worsening of chronic heart failure requiring vasoactive drug therapy
  3. severe infections, septicaemia
  4. severe hepatic insufficiency ( Child-Pugh class C)
  5. severe renal insufficiency ( chronic kidney disease (CKD) stage 5: estimated glomerular filtration rate (eGFR) <15ml/min or dialysis)
  6. hypotensive state, shock ( systolic blood pressure <90mmHg or mean arterial pressure <70mmHg with tissue hypoperfusion and urine output <30ml/h)
  7. uncontrolled diseases of the haematological system: acute gastrointestinal bleeding, intracranial haemorrhage or haemorrhage from other organs, acute pulmonary embolism or deep vein thrombosis, congenital or acquired haemorrhagic disease such as haemophilia, anaphylactic purpura and acute leukaemia, severe abnormalities in haematological parameters such as platelet count <20*10^9/l and international normalized ratio (INR) >3
  8. contraindication for Trans-Esophageal Echocardiography (TEE) such as oesophageal constriction, oesophageal tumour, oesophageal fistula, oesophageal varices, cervical vertebral instability
  9. contraindication for CMR such as metal foreign matter in the body, claustrophobia
  10. contraindication for intravenous anaesthesia such as allergy to anaesthetics
  11. pregnancy or breastfeeding
  12. The patient does not sign an informed consent form.
  13. Due to other reasons the patient is not suitable for enrollment assessed by the researcher.

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

150 participants in 4 patient groups

UCG in pre-anaesthetic group
Other group
Description:
The fasting patients receive UCG in pre-anaesthetic.
Treatment:
Other: fasting
Diagnostic Test: UCG
UCG in post-anaesthetic group
Other group
Description:
The fasting patients receive UCG in post-anaesthetic.
Treatment:
Other: fasting
Diagnostic Test: UCG
UCG in post-rehydration group
Other group
Description:
The fasting patients in anaesthetised receive UCG in post-rehydration.
Treatment:
Other: rehydration
Other: fasting
Diagnostic Test: UCG
cardiac magnetic resonance (CMR) group
Other group
Description:
The non-fasting patients receive CMR in another time.
Treatment:
Diagnostic Test: CMR

Trial contacts and locations

1

Loading...

Central trial contact

Maohuan Lin, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems